SELLAS Life Sciences Group, Inc. Increase (Decrease) in Accounts Receivable
SELLAS Life Sciences Group, Inc. (SLS) reported Increase (Decrease) in Accounts Receivable of $0 for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsReceivable · last filed 2023-05-11
- SELLAS Life Sciences Group, Inc. increase (decrease) in accounts receivable for the quarter ending 2023-03-31 was $0.00, a 100.00% decline year-over-year.
- SELLAS Life Sciences Group, Inc. increase (decrease) in accounts receivable for the quarter ending 2022-03-31 was $1.00M.
- SELLAS Life Sciences Group, Inc. increase (decrease) in accounts receivable for the quarter ending 2015-06-30 was $758.00K, a 10.50% increase year-over-year.
- SELLAS Life Sciences Group, Inc. increase (decrease) in accounts receivable for the quarter ending 2015-03-31 was -$779.00K.
- SELLAS Life Sciences Group, Inc. increase (decrease) in accounts receivable for fiscal 2014 was -$1.64M, a 144.64% decline from fiscal 2013.
- SELLAS Life Sciences Group, Inc. increase (decrease) in accounts receivable for fiscal 2013 was $3.68M.
- SELLAS Life Sciences Group, Inc. increase (decrease) in accounts receivable for fiscal 2012 was $0.00.
- SELLAS Life Sciences Group, Inc. increase (decrease) in accounts receivable for fiscal 2011 was $0.00.
| Period end | Increase (Decrease) in Accounts Receivable 3 month | Increase (Decrease) in Accounts Receivable 6 month | Increase (Decrease) in Accounts Receivable 9 month | Increase (Decrease) in Accounts Receivable 12 month |
|---|---|---|---|---|
| 2023-03-31 | $0.00 10-Q · filed 2023-05-11 | |||
| 2022-03-31 | $1.00M 10-Q · filed 2023-05-11 | |||
| 2015-06-30 | $758.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$21.00K 10-Q · filed 2015-08-06 | $583.00K derived: sum of 3 quarters · filed 2015-08-06 | -$134.00K derived: sum of 4 quarters · filed 2015-08-06 |
| 2015-03-31 | -$779.00K 10-Q · filed 2015-05-07 | -$175.00K derived: sum of 2 quarters · filed 2015-05-07 | -$892.00K derived: sum of 3 quarters · filed 2015-05-07 | -$206.00K derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-12-31 | $604.00K derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-05 | -$113.00K derived: sum of 2 quarters · filed 2015-03-05 | $573.00K derived: sum of 3 quarters · filed 2015-08-06 | -$1.64M 10-K · filed 2015-03-05 |
| 2014-09-30 | -$717.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | -$31.00K derived: sum of 2 quarters · filed 2015-08-06 | -$2.25M 10-Q · filed 2014-11-05 | -$108.00K derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-06-30 | $686.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06 | -$1.53M 10-Q · filed 2015-08-06 | $609.00K derived: sum of 3 quarters · filed 2015-08-06 | $2.15M derived: sum of 4 quarters · filed 2015-08-06 |
| 2014-03-31 | -$2.22M 10-Q · filed 2015-05-07 | -$77.00K derived: sum of 2 quarters · filed 2015-05-07 | $1.47M derived: sum of 3 quarters · filed 2015-05-07 | $1.47M derived: sum of 4 quarters · filed 2015-05-07 |
| 2013-12-31 | $2.14M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-05 | $3.68M derived: sum of 2 quarters · filed 2015-03-05 | $3.68M derived: sum of 3 quarters · filed 2015-03-05 | $3.68M 10-K · filed 2015-03-05 |
| 2013-09-30 | $1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-05 | $1.54M derived: sum of 2 quarters · filed 2014-11-05 | $1.54M 10-Q · filed 2014-11-05 | $1.54M derived: sum of 4 quarters · filed 2015-03-05 |
| 2013-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-11 | $0.00 10-Q · filed 2014-08-11 | $0.00 derived: sum of 3 quarters · filed 2015-03-05 | |
| 2013-03-31 | $0.00 10-Q · filed 2014-05-06 | $0.00 derived: sum of 2 quarters · filed 2015-03-05 | ||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q/A 9 month · filed 2015-03-05 | $0.00 10-K · filed 2015-03-05 | ||
| 2012-09-30 | $0.00 10-Q/A · filed 2013-11-07 | |||
| 2011-12-31 | $0.00 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |